Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

Illumina's (NASDAQ: ILMN) first-quarter results were full of exclamation points -- at least from an investor's perspective. Revenue jumped nearly 31% year over year. Adjusted earnings per share more ...

On Feb 16, we issued an updated research report on Illumina, Inc. ILMN. The company’s market opportunities continue to expand owing to accelerated demand from clinical and translational customers.

Canaccord Genuity analyst Kyle Mikson CFA has maintained their neutral stance on ILMN stock, giving a Hold rating today. Geoff Meacham has given his Hold rating due to a combination of factors ...

The "Microarray Analysis Market by Product & Service (Consumables, Instrument, Software, Services), Type, Application (Research), End User (Diagnostic Laboratories, Pharmaceutical & Biotechnology ...